CORRECTED-UPDATE 2-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

MÅLØV, Denmark, Nov 21 (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes drugs come under pressure, particularly in the United States.